Benzinga | Nov 15, 2021 10:57AM EST

Zynerba Pharmaceuticals Q3 EPS $(0.26) Misses $(0.25) Estimate

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 16.13 percent increase over losses of $(0.31) per share from the same period last year.